TG6-10-1
规格
| Cas Number | 1415716-58-3 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 50mg 或 10mg 或 5mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 100 mg/mL (223.00 mM; Need ultrasonic) |
| 过滤标签 | Prostaglandin Receptor,5-HT Receptor,GPCR/G Protein,神经元信号传导 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | TG6-10-1 是一种 EP2 拮抗剂，仅对 EP2 具有低纳摩尔的拮抗活性，对人类 EP3、EP4 和 IP 受体的选择性大于 300 倍，对 EP1 受体的选择性为 100 倍。 |
| 英文描述 |
TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors In Vitro TG6-10-1 robustly blocks prostaglandin E2 (PGE2) (10 μM)-induced cAMP accumulation in a concentration-dependent manner in SH-SY5Y cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo TG6-10-1 (5 mg/kg; i.p.; 4-30 hours) improves survival, accelerates recovery of lost weight, and improves functional recovery following status epilepticus (SE) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice (pilocarpine-induced SE) Dosage: 5 mg/kg Administration: Intraperitoneal injection; 4, 21, 30 hours Result: A significant increase in survival and accelerating the recovery of lost weight in post-SE mice. Form:Solid IC50& Target:EP2 |